EXAS

Exact Sciences Corporation (EXAS) | Rumor.io

Exact Sciences

EXAS

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)91%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about EXAS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 3

The author compares the current situation to Exact Sciences' price drop from $25 to $5, suggesting a potential fear-driven sell-off.
The author shares their personal experience of buying more shares during the dip and selling at significant gains later.
The author attributes the price drop to investors losing conviction and selling, leading to a fear cascade.

Generated by AI

Sentiment

Of the messages about EXAS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +3.94	95.77% +15.77
Bearish	—	—	0% -3.94	4.23% -15.77

Bullish· Nov 21

$EXAS has seen a +76% move higher following its downtrend resistance breakout, with strong follow-through within the chart.
The acquisition of $EXAS by Abbott at $105/share is a significant rally for the stock, with many investors expecting it to reach $105-$110 in the short term.
The acquisition deal is expected to close in Q2 2026, with investors having the option to wait for the $105/share payout or take a slight pay cut to cash out and move their money elsewhere.

Bearish· Nov 13

* Exact Sciences Corporation's ($EXAS) Oncotype DX reimbursements have been cut, negatively impacting sentiment.
* The reimbursement cuts for Oncotype DX, a key product of $EXAS, may lead to reduced sales and revenue.
* The sentiment surrounding $EXAS has been negatively impacted by the reimbursement cuts for Oncotype DX.

Generated by AI

Topics

Of the messages about EXAS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	45.51%
Announcements	—	100%	100%	7.48%
Controversies	—	0%	0%	0.26%
Earnings	—	0%	0%	0.42%
Macro	—	0%	0%	45.11%
Technical Analysis	—	0%	0%	1.22%

Earnings· May 9

Exact Sciences Corporation ($EXAS) reported Q1 GAAP EPS of -$0.42, beating estimates by $0.34.
Revenue of $602.45M also beat estimates by $59.27M, with a 24% year-over-year increase.
The company raised FY23 revenue guidance to $2.38B-$2.42B, exceeding consensus estimates of $2.3B.

Analysts· Feb 23

SVB Leerink analyst Puneet Souda maintains Exact Sciences with an Outperform rating and lowers the price target from $140 to $130.
Raymond James analyst Andrew Cooper maintains Exact Sciences with an Outperform rating and lowers the price target from $130 to $90.
Wells Fargo analyst lowers the price target for Exact Sciences from $95 to $80.

Announcements· Mar 26

Abbott Labs has completed its acquisition of Exact Sciences Corporation, with the deal closing on March 23, 2026.
Exact Sciences will now operate under Abbott's ownership.
The merger was approved by shareholders on February 20, 2026, with Exact Sciences reporting $3.25B in revenue and a net loss of $207.95M in its most recent fiscal year.

Technical Analysis· Oct 27

$EXAS has shown an impulsive move with volume, followed by consolidation, and may be preparing for a measured move.
The stock has a bullish setup, consolidating above previous major resistance, with a potential breakout in the pre-market and a good risk-reward opportunity.
$EXAS has shown a parabolic run, but may be experiencing exhaustion, with some analysts expecting a reversal after a double top formation.

Generated by AI

Community

Of the messages about EXAS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	9.09%	15.79%	71.43%
Newcomers	—	90.91%	84.21%	28.57%

Regulars· Nov 21

Abbott's acquisition of Exact Sciences for $21 billion is a significant development, with Cologuard and Oncotype DX joining Abbott's diagnostics lineup, and Exact Sciences shares jumping 18%.
The acquisition is a result of Exact Sciences' COVID-19 test revenue declining, and Abbott's bid of $105 per share represents a 22% premium.
Analysts are side-eyeing the deal, and the sector is being closely watched, with some considering Aligned (ALGN) a potential buyout candidate.

Newcomers· Mar 27

Many traders are focusing on the recent 12% move in NXXT, with some attributing it to positioning before the company's report.
The attention and market momentum surrounding NXXT's 6.52% gain are being compared to its usual overnight fade, with some traders concerned about the implications.
Newcomers are highlighting NXXT's potential, citing its process, scale, and orchestration, as well as its compliance and procurement logic, as attractive features.

Generated by AI

News

Abbott investigates two separate cyber incidents, says no operations affected

2mo agoReuters

Why Abbott Stock Jumped Today

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Abbott raises 2026 profit forecast on strength in diagnostics, heart devices

July 16 () - Abbott beat estimates for quarterly results and raised its annual profit forecast on Thursday, ‌banking on strong demand for its newly acquired ‌cancer diagnostics business, sending its shares up nearly 4% premarket. Abbott said its cancer diagnostics business, which now includes recently acquired Exact Sciences' flagship colorectal cancer screening test, Cologuard, and breast cancer assay Oncotype DX, is helping offset ongoing declines in ‌revenue from COVID-19 testing ⁠products.

2mo agoYahoo Finance

Abbott Q2 2026 earnings beat, raises full-year profit guidance

The healthcare company posted adjusted earnings of $1.31 a share in the second quarter, topping Wall Street's estimate of $1.28

2mo agoYahoo Finance

Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition

2mo agoSeeking Alpha

Also Discussed

Investors talking about EXAS also mention

#	Name	Attention
1	Guardant Health Inc.GH	0%-0.11
2	Mainz Biomed N.V.MYNZ	0%new
3	Natera, Inc.NTRA	0%-0.01
4	Myriad Genetics Inc.MYGN	0%0
5	Veracyte, Inc.VCYT	0%new
6	Illumina Inc.ILMN	0%+0
7	Exelixis Inc.EXEL	0%-0.03
8	NVTA - Invitae Corporation	——
9	SGEN - Seagen Inc.	——
10	FOLD - Amicus Therapeutics, Inc.	——

Exact Sciences Corporation

Location

Social

What share of all stock conversation is about EXAS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jun 3

The author compares the current situation to Exact Sciences' price drop from $25 to $5, suggesting a potential fear-driven sell-off.
The author shares their personal experience of buying more shares during the dip and selling at significant gains later.
The author attributes the price drop to investors losing conviction and selling, leading to a fear cascade.

Generated by AI

Sentiment

Of the messages about EXAS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +3.94	95.77% +15.77
Bearish	—	—	0% -3.94	4.23% -15.77

Bullish· Nov 21

$EXAS has seen a +76% move higher following its downtrend resistance breakout, with strong follow-through within the chart.
The acquisition of $EXAS by Abbott at $105/share is a significant rally for the stock, with many investors expecting it to reach $105-$110 in the short term.
The acquisition deal is expected to close in Q2 2026, with investors having the option to wait for the $105/share payout or take a slight pay cut to cash out and move their money elsewhere.

Bearish· Nov 13

* Exact Sciences Corporation's ($EXAS) Oncotype DX reimbursements have been cut, negatively impacting sentiment.
* The reimbursement cuts for Oncotype DX, a key product of $EXAS, may lead to reduced sales and revenue.
* The sentiment surrounding $EXAS has been negatively impacted by the reimbursement cuts for Oncotype DX.

Generated by AI

Topics

Of the messages about EXAS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	45.51%
Announcements	—	100%	100%	7.48%
Controversies	—	0%	0%	0.26%
Earnings	—	0%	0%	0.42%
Macro	—	0%	0%	45.11%
Technical Analysis	—	0%	0%	1.22%

Earnings· May 9

Exact Sciences Corporation ($EXAS) reported Q1 GAAP EPS of -$0.42, beating estimates by $0.34.
Revenue of $602.45M also beat estimates by $59.27M, with a 24% year-over-year increase.
The company raised FY23 revenue guidance to $2.38B-$2.42B, exceeding consensus estimates of $2.3B.

Analysts· Feb 23

SVB Leerink analyst Puneet Souda maintains Exact Sciences with an Outperform rating and lowers the price target from $140 to $130.
Raymond James analyst Andrew Cooper maintains Exact Sciences with an Outperform rating and lowers the price target from $130 to $90.
Wells Fargo analyst lowers the price target for Exact Sciences from $95 to $80.

Announcements· Mar 26

Abbott Labs has completed its acquisition of Exact Sciences Corporation, with the deal closing on March 23, 2026.
Exact Sciences will now operate under Abbott's ownership.
The merger was approved by shareholders on February 20, 2026, with Exact Sciences reporting $3.25B in revenue and a net loss of $207.95M in its most recent fiscal year.

Technical Analysis· Oct 27

$EXAS has shown an impulsive move with volume, followed by consolidation, and may be preparing for a measured move.
The stock has a bullish setup, consolidating above previous major resistance, with a potential breakout in the pre-market and a good risk-reward opportunity.
$EXAS has shown a parabolic run, but may be experiencing exhaustion, with some analysts expecting a reversal after a double top formation.

Generated by AI

Community

Of the messages about EXAS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	9.09%	15.79%	71.43%
Newcomers	—	90.91%	84.21%	28.57%

Regulars· Nov 21

Abbott's acquisition of Exact Sciences for $21 billion is a significant development, with Cologuard and Oncotype DX joining Abbott's diagnostics lineup, and Exact Sciences shares jumping 18%.
The acquisition is a result of Exact Sciences' COVID-19 test revenue declining, and Abbott's bid of $105 per share represents a 22% premium.
Analysts are side-eyeing the deal, and the sector is being closely watched, with some considering Aligned (ALGN) a potential buyout candidate.

Newcomers· Mar 27

Many traders are focusing on the recent 12% move in NXXT, with some attributing it to positioning before the company's report.
The attention and market momentum surrounding NXXT's 6.52% gain are being compared to its usual overnight fade, with some traders concerned about the implications.
Newcomers are highlighting NXXT's potential, citing its process, scale, and orchestration, as well as its compliance and procurement logic, as attractive features.

Generated by AI

Exact Sciences

Social

Jun 3

Bullish· Nov 21

Bearish· Nov 13

Earnings· May 9

Analysts· Feb 23

Announcements· Mar 26

Technical Analysis· Oct 27

Regulars· Nov 21

Newcomers· Mar 27

Abbott investigates two separate cyber incidents, says no operations affected

Why Abbott Stock Jumped Today

Abbott raises 2026 profit forecast on strength in diagnostics, heart devices

Abbott Q2 2026 earnings beat, raises full-year profit guidance

Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition

Also Discussed

Exact Sciences Corporation

Company Information

Location

Social

Jun 3

Bullish· Nov 21

Bearish· Nov 13

Earnings· May 9

Analysts· Feb 23

Announcements· Mar 26

Technical Analysis· Oct 27

Regulars· Nov 21

Newcomers· Mar 27

Abbott investigates two separate cyber incidents, says no operations affected

Why Abbott Stock Jumped Today

Abbott raises 2026 profit forecast on strength in diagnostics, heart devices

Abbott Q2 2026 earnings beat, raises full-year profit guidance

Abbott Laboratories Q2 preview: Analysts see healthy growth backed by Exact Sciences acquisition

Also Discussed